Clinical Trial

Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 29, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Assessment of immunogenicity, reactogenicity and safety of GNG-DE in comparison with the reference drug
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-13; most recent amendment 2025-12-24.
Status change: Not Yet Recruiting → Recruiting 2025-07-09
Trial Details
NCT Number NCT06834100
Lead Sponsor NPO Petrovax
Conditions Infections, Meningococcal
Enrollment 240 participants
Start Date 2025-02-12
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-29